{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:04:41Z","timestamp":1789682681924,"version":"4.0.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T00:00:00Z","timestamp":1649030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T00:00:00Z","timestamp":1649030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"uniQure Biophpharma BV","award":["2-061.003"],"award-info":[{"award-number":["2-061.003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Gene therapy has the potential to change the life experience of people with haemophilia and family members. Few studies have sought to explore the impact of gene therapy on both individuals and families. The aim of this study was to capture real-life experiences of gene therapy in People with haemophilia and their families.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Sixteen participants with severe haemophilia (11 haemophilia A, five haemophilia B), mean age 41.4\u00a0years (range 23\u201375\u00a0years), took part in a single qualitative interview; ten were accompanied by a family member. Mean time since transfection was 3.56\u00a0years (range 1\u201310\u00a0years). Participants saw their involvement in gene therapy as a positive experience, freeing them from the personal burden of haemophilia and furthering treatment options for the wider haemophilia community. However, participants reported being unprepared for the side effects of immunosuppression. Some also reported feeling unsupported and having little control over what was happening as their factor levels became the focus of the process.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The results suggest that strategies need to be put into place to enable PwH fully to understand the process of gene therapy, and thereby make an informed choice as to whether it is a treatment they might wish for themselves. These include early and ongoing education, increased provision of psychosocial support and ongoing qualitative research.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13023-022-02256-2","type":"journal-article","created":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T14:02:45Z","timestamp":1649080965000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["The experiences of people with haemophilia and their families of gene therapy in a clinical trial setting: regaining control, the Exigency study"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9018-6176","authenticated-orcid":false,"given":"Simon","family":"Fletcher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2704-0606","authenticated-orcid":false,"given":"Kathryn","family":"Jenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2024-6898","authenticated-orcid":false,"given":"Luke","family":"Pembroke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9173-4100","authenticated-orcid":false,"given":"Michael","family":"Holland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2001-5958","authenticated-orcid":false,"given":"Kate","family":"Khair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,4]]},"reference":[{"key":"2256_CR1","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1111\/hae.14012","volume":"27","author":"JS Stonebraker","year":"2020","unstructured":"Stonebraker JS, Bolton-Maggs PHB, Brooker M, Evatt B, Iorio A, Makris M, O\u2019Mahony B, Skinner MW, Coffin D, Pierce GF, Tootoonchian E. The world federation of Hemophilia Annual Global Survey 1999\u20132018. Haemophilia. 2020;27:591\u2013600. https:\/\/doi.org\/10.1111\/hae.14012.","journal-title":"Haemophilia"},{"key":"2256_CR2","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1002\/ajh.24218","volume":"90","author":"R Curtis","year":"2015","unstructured":"Curtis R, Baker J, Riske B, et al. Young adults with hemophilia in the U.S.: demographics, comorbidities, and health status. Am J Hematol. 2015;90:S11\u20136. https:\/\/doi.org\/10.1002\/ajh.24218.","journal-title":"Am J Hematol"},{"issue":"6","key":"2256_CR3","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1056\/nejme078098","volume":"357","author":"M Manco-Johnson","year":"2007","unstructured":"Manco-Johnson M, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, Ingram JD, Manco-Johnson ML, Funk S, Jacobson L, Valentino LA, Hoots WK, Buchanan GR, DiMichele D, Recht M, Brown D, Cindy L, Bleak S, Cohen A, Mathew P, Matsunaga A, Medeiros D, Nugent D, Thomas GA, Thompson AA, McRedmond K, Soucie JM, Austin H, Evatt BL. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe Hemophilia. N Engl J Med. 2007;357(6):535\u201344. https:\/\/doi.org\/10.1056\/nejme078098.","journal-title":"N Engl J Med"},{"key":"2256_CR4","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/j.1365-2141.2010.08139.x","volume":"149","author":"M Richards","year":"2010","unstructured":"Richards M, Williams M, Chalmers E, Liesner R, Collins P, Vidler V, Hanley J, on behalf of the Paediatric Working Party of the United Kingdom Haemophilia Doctors\u2019 Organisation. A United Kingdom Haemophilia Centre Doctors\u2019 Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A. Br J Haematol. 2010;149:498\u2013507. https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08139.x.","journal-title":"Br J Haematol"},{"key":"2256_CR5","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1111\/hae.14046","volume":"26","author":"A Srivastava","year":"2020","unstructured":"Srivastava A, Santagostino E, Dougall A, Kitchen SS, Sutherland M, Pipe SW, Carcao M, Mahlangu J, Ragni MV, Windyga J, Lin\u00e1s A, Goddard NJ, Mohan R, Poonose PM, Feldman BM, Lewis SZ, van den Berg H, Pierce GF, on behalf of the WFH Guidelines for the Management of Hemophilia panellists and co-authors. WFH guidelines for the management of Hemophilia, 3rd edition. Haemophilia. 2020;26:S1-158. https:\/\/doi.org\/10.1111\/hae.14046.","journal-title":"Haemophilia"},{"key":"2256_CR6","doi-asserted-by":"publisher","first-page":"e228","DOI":"10.1111\/hae.12121","volume":"19","author":"A Farrugia","year":"2013","unstructured":"Farrugia A, Cassar J, Kimber MC, Bansal M, Fischer K, Auserswald G, O\u2019Mahony B, Tolley K, Noone D, Balboniet S. Treatment for life for severe hemophilia A-A cost-utility model for prophylaxis vs. on-demand treatment. Haemophilia. 2013;19:e228\u201338. https:\/\/doi.org\/10.1111\/hae.12121.","journal-title":"Haemophilia"},{"key":"2256_CR7","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1080\/13696998.2021.1891088","volume":"24","author":"N Li","year":"2021","unstructured":"Li N, Sawyer EK, Maruszczyk K, Guzauskas G, Slomka MT, Burke T, Martin AP, O\u2019Hara J, Stevenson M, Recht M. Adult lifetime cost of hemophilia B management in the US: Payer and societal perspectives from a decision analytic model. J Med Econ. 2021;24:363\u201372. https:\/\/doi.org\/10.1080\/13696998.2021.1891088.","journal-title":"J Med Econ"},{"key":"2256_CR8","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1703068","volume":"377","author":"J Oldenburg","year":"2017","unstructured":"Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, Santagostino E, Kruse-Jarres R, Negrier C, Kessler C, Valente N, Asikanius E, Levy GG, Windyga J, Shima M. Emicizumab prophylaxis in Hemophilia A with inhibitors. NEJM. 2017;377:809\u201318. https:\/\/doi.org\/10.1056\/NEJMoa1703068.","journal-title":"NEJM"},{"key":"2256_CR9","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1182\/blood.2019001869","volume":"134","author":"G Young","year":"2019","unstructured":"Young G, Liesner R, Chang T, Sidonio R Jr, Oldenburg J, Jim\u00e9nez-Yuste V, Mahlangu J, Kruse-Jarres R, Wang M, Uguen M, Doral MY, Wright LY, Schmitt C, Levy GG, Shima M, Mancuso ME. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019;134:2127\u201338. https:\/\/doi.org\/10.1182\/blood.2019001869.","journal-title":"Blood"},{"issue":"6","key":"2256_CR10","doi-asserted-by":"publisher","first-page":"e295","DOI":"10.1016\/S2352-3026(19)30054-7","volume":"6","author":"S Pipe","year":"2019","unstructured":"Pipe S, Shima M, Lehle M, Shapiro A, Chebon S, Fukutake K, Key N, Portron A, Schmitt C, Podolak-Dawidziak M, Bienz N, Hermans C, Campinha-Bacote A, Kiialainen A, Peerlinck K, Levy G, Jimenez-Yuste V. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol. 2019;6(6):e295\u2013305. https:\/\/doi.org\/10.1016\/S2352-3026(19)30054-7.","journal-title":"Lancet Haematol"},{"key":"2256_CR11","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","volume":"365","author":"AC Nathwani","year":"2011","unstructured":"Nathwani AC, Tuddenham EGD, Rangarajan S, Rosales C, McIntosh J, Linch DC. Adenovirus-associated virus vector-mediated gene transfer in haemophilia B. N Engl J Med. 2011;365:2357\u201365. https:\/\/doi.org\/10.1056\/NEJMoa1108046.","journal-title":"N Engl J Med"},{"key":"2256_CR12","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","volume":"371","author":"AC Nathwani","year":"2014","unstructured":"Nathwani AC, Reiss UM, Tuddenham EGD, Rosales C, Chowdary P, McIntosh J, Peruta MD, Lheriteau E, Patel N, Raj D, Riddell A, Pie J, Rangarajan S, Bevan D, Recht M, Shen YM, Halka KG, Basner-Tschakarjan E, Mingozzi F, High KA, Allay J, Kay MA, Ng CYC, Zhou J, Cancio M, Morton CL, Gray JT, Srivastava D, Nienhuis AW, Davidoff AM. Long-term safety and efficacy of factor IX gene therapy in haemophilia B. N Engl J Med. 2014;371:1994\u20132004. https:\/\/doi.org\/10.1056\/NEJMoa1407309.","journal-title":"N Engl J Med"},{"key":"2256_CR13","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1182\/blood-2018-07-820720","volume":"33","author":"GQ Perin","year":"2018","unstructured":"Perin GQ, Herzog RW, Markusic DM. Update of clinical gene therapy for haemophilia. Blood. 2018;33:407\u201314. https:\/\/doi.org\/10.1182\/blood-2018-07-820720.","journal-title":"Blood"},{"key":"2256_CR14","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","volume":"377","author":"S Rangarajan","year":"2017","unstructured":"Rangarajan S, Walsh L, Lester W, Perry D, Madan B, Laffan M, Yu H, Vettermann C, Pierce GF, Wong WY, Pasi KJ. AAV5\u2013factor VIII gene transfer in severe haemophilia A. N Engl J Med. 2017;377:2519\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1708483.","journal-title":"N Engl J Med"},{"key":"2256_CR15","unstructured":"United Kingdom Haemophilia Doctors\u2019 Organisation. The UKHCDO annual report and bleeding disorder statistics for the financial year 2019\u20132020. Manchester: United Kingdom Haemophilia Doctors\u2019 Organisation; 2021. http:\/\/www.ukhcdo.org\/wp-content\/uploads\/2021\/03\/UKHCDO-Annual-Report-2020-2019-20-Data_FINAL.pdf. Accessed 12 Mar 2021."},{"key":"2256_CR16","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1182\/blood-2018-07-820720","volume":"17","author":"K Brown","year":"2018","unstructured":"Brown K, Green G. The haemophilia drug market. Nat Rev Drug Discov. 2018;17:541\u20132. https:\/\/doi.org\/10.1182\/blood-2018-07-820720.","journal-title":"Nat Rev Drug Discov"},{"key":"2256_CR17","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/hae.13673","volume":"25","author":"G Pierce","year":"2019","unstructured":"Pierce G, Coffin D, Members of the WFH Gene Therapy Round Table Program Committee and Organizing Committee. The 1st WFH Gene Therapy Round Table: understanding the landscape and challenges of gene therapy for haemophilia around the world. Haemophilia. 2019;25:189\u201394. https:\/\/doi.org\/10.1111\/hae.13673.","journal-title":"Haemophilia"},{"key":"2256_CR18","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/hae.14190","volume":"27","author":"E van Overbeeke","year":"2020","unstructured":"van Overbeeke E, Michelsen S, Hauber B, et al. Patient perspectives regarding gene therapy in haemophilia: interviews from the PAVING study. Haemophilia. 2020;27:129\u201336. https:\/\/doi.org\/10.1111\/hae.14190.","journal-title":"Haemophilia"},{"key":"2256_CR19","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/hae.14378","volume":"27","author":"S Fletcher","year":"2021","unstructured":"Fletcher S, Jenner K, Holland M, Chaplin S, Khair K. An exploration of why men with severe haemophilia might not want gene therapy: the exigency study. Haemophilia. 2021;27:760\u20138. https:\/\/doi.org\/10.1111\/hae.14378.","journal-title":"Haemophilia"},{"key":"2256_CR20","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40271-019-00395-6","volume":"13","author":"EC van Balen","year":"2020","unstructured":"van Balen EC, Wesselo ML, Baker BL, Westerman MJ, Coppens M, Smit C, Driessens MHE, Leebeek FWG, van der Bom JG, Gouw SC. Patient perspectives on novel treatments in haemophilia: a qualitative study. Patient. 2020;13:201\u201310. https:\/\/doi.org\/10.1007\/s40271-019-00395-6.","journal-title":"Patient"},{"key":"2256_CR21","doi-asserted-by":"publisher","first-page":"767","DOI":"10.2147\/PPA.S239810","volume":"14","author":"W Meisbach","year":"2020","unstructured":"Meisbach W, Klamroth R. The patient experience of gene therapy for haemophilia: qualitative interviews with trial patients. Patient Preference Adherence. 2020;14:767\u201370. https:\/\/doi.org\/10.2147\/PPA.S239810.","journal-title":"Patient Preference Adherence"},{"key":"2256_CR22","doi-asserted-by":"publisher","DOI":"10.17225\/jhp00174","author":"E Aradom","year":"2021","unstructured":"Aradom E, Gomez K. The patient gene therapy journey: findings from qualitative interviews with trial participants at one UK Haemophilia centre. J Haemophilia Pract. 2021. https:\/\/doi.org\/10.17225\/jhp00174.","journal-title":"J Haemophilia Pract"},{"key":"2256_CR23","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/oso\/9780195168655.003.0038","volume-title":"The Oxford textbook of clinical research ethics","author":"FG Miller","year":"2008","unstructured":"Miller FG. Recruiting research participants. In: Emanuel EJ, Grady C, Crouch RA, Lie RK, Miller FG, Wender D, editors. The Oxford textbook of clinical research ethics. Oxford: Oxford University Press; 2008. p. 397\u2013403."},{"key":"2256_CR24","first-page":"82","volume-title":"Participation in human inquiry","author":"E Whitmore","year":"1994","unstructured":"Whitmore E. To tell the truth: Working with oppressed groups in participatory approaches to inquiry. In: Reason P, editor. Participation in human inquiry. London: Sage; 1994. p. 82\u201398."},{"key":"2256_CR25","first-page":"21","volume-title":"Exploring clinical methods for social research","author":"DN Berg","year":"1985","unstructured":"Berg DN, Smith KK. The clinical demands of research methods. In: Berg DN, Smith KK, editors. Exploring clinical methods for social research. Beverly Hills: Sage; 1985. p. 21\u201334."},{"issue":"4","key":"2256_CR26","doi-asserted-by":"publisher","first-page":"7","DOI":"10.7748\/nr2007.07.14.4.7.c6039","volume":"14","author":"M Simmons","year":"2007","unstructured":"Simmons M. Insider ethnography: tinker, tailor, researcher or spy? Nurse Res. 2007;14(4):7\u201317. https:\/\/doi.org\/10.7748\/nr2007.07.14.4.7.c6039.","journal-title":"Nurse Res"},{"key":"2256_CR27","first-page":"S65","volume":"24","author":"S Rangarajan","year":"2018","unstructured":"Rangarajan S, Kim B, Lester W, Symington E, Madan B, Laffan M, Tavakkoli F, Pierce G, Wong WY, Pasi J. Achievement of normal factor VIII activity following gene transfer with valoctocogene roxaparvovec (BMN 270): long-term efficacy and safety results in patients with severe hemophilia A. Haemophilia. 2018;24:S65.","journal-title":"Haemophilia"},{"key":"2256_CR28","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1182\/BLOOD-2018-99-115495","volume":"132","author":"KA High","year":"2018","unstructured":"High KA, George LA, Eyster E, Sullivan SK, Ragni MV, Croteau SE, Samelson-Jones BJ, Evans M, Joseney-Antoine M, Macdougall A, et al. A phase 1\/2 trial of investigational Spk-8011 in hemophilia a demonstrates durable expression and prevention of bleeds. Blood. 2018;132:92\u20135856. https:\/\/doi.org\/10.1182\/BLOOD-2018-99-115495.","journal-title":"Blood"},{"key":"2256_CR29","doi-asserted-by":"publisher","first-page":"R95","DOI":"10.1093\/hmg\/ddz157","volume":"28","author":"P Batty","year":"2019","unstructured":"Batty P, Lillicrap D. Advances and challenges for hemophilia gene therapy. Hum Mol Genet. 2019;28:R95\u2013101. https:\/\/doi.org\/10.1093\/hmg\/ddz157.","journal-title":"Hum Mol Genet"},{"key":"2256_CR30","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/mt.2010.274","volume":"19","author":"AC Nathwani","year":"2011","unstructured":"Nathwani AC, Rosales C, McIntosh J, Rastegarlari G, Nathwani D, Raj D, Nawathe S, Waddington SN, Bronson R, Jackson S, Donahue RE, High KA, Mingozzi F, Ng CYC, Zhou J, Spence Y, McCarville MB, Valentine M, Allay J, Coleman J, Sleep S, Gray JT, Nienhuis AW, Davidoff AM. Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotypedwith serotype 5 and 8 capsid proteins. Mol Ther. 2011;19:876\u201385.","journal-title":"Mol Ther"},{"key":"2256_CR31","doi-asserted-by":"publisher","first-page":"S3331","DOI":"10.1182\/blood.V130.Suppl_1.3331.3331","volume":"130","author":"S Pipe","year":"2017","unstructured":"Pipe S, Stine K, Rajasekhar A, Everington T, Poma A, Crombez E, Hay CRM. 101HEMB01 is a phase 1\/2 open-label, single ascending dose-finding trial of DTX101 AAVrh10FIX in patients with moderate\/severe hemophilia B that demonstrated meaningful but transient expression of human factor IX hFIX. Blood. 2017;130:S3331. https:\/\/doi.org\/10.1182\/blood.V130.Suppl_1.3331.3331.","journal-title":"Blood"},{"key":"2256_CR32","unstructured":"National Institute of Health and Care Excellence. British National Formulary. 2021. https:\/\/bnf.nice.org.uk\/treatment-summary\/corticosteroids-general-use.html. Accessed 12 Sept 2021."},{"key":"2256_CR33","doi-asserted-by":"publisher","DOI":"10.1093\/med\/9780190459277.001.0001","volume-title":"Silent partners: human subjects and research ethics","author":"R Dresser","year":"2016","unstructured":"Dresser R. Silent partners: human subjects and research ethics. Oxford: Oxford University Press; 2016."},{"key":"2256_CR34","unstructured":"Quality Review Services. Inherited and acquired haemophilia and other bleeding disorders peer review programme: overview report. 2020. https:\/\/images.qualityreviewservicewm.nhs.uk\/wp-content\/uploads\/2020\/05\/28154818\/IABD-Overview-Report-2020-V1-20200527-1.pdf. Accessed 14 Sept 2021."},{"key":"2256_CR35","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/hae.14188","volume":"27","author":"K Khair","year":"2021","unstructured":"Khair K, Steadman L, Chaplin S, Holland M, Jenner K, Fletcher S. Parental perspectives on gene therapy for children with haemophilia: the Exigency study. Haemophilia. 2021;27:120\u20138. https:\/\/doi.org\/10.1111\/hae.14188.","journal-title":"Haemophilia"},{"key":"2256_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/26330040211047244","volume":"2","author":"L Woollard","year":"2021","unstructured":"Woollard L, Gorman R, Rosenfelt DJ. Improving patient informed consent for haemophilia gene therapy: the case for change. Ther Adv Rare Dis. 2021;2:1\u201316. https:\/\/doi.org\/10.1177\/26330040211047244.","journal-title":"Ther Adv Rare Dis"},{"key":"2256_CR37","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.46743\/2160-3715\/2015.2281","volume":"20","author":"PI Fusch","year":"2015","unstructured":"Fusch PI, Ness LR. Are we there yet? Data saturation in qualitative research. Qual Rep. 2015;20:1408\u201316. https:\/\/doi.org\/10.46743\/2160-3715\/2015.2281.","journal-title":"Qual Rep"},{"key":"2256_CR38","volume-title":"Social research methods: qualitative and quantitative approaches","author":"RH Bernard","year":"2012","unstructured":"Bernard RH. Social research methods: qualitative and quantitative approaches. 2nd ed. Thousand Oaks: Sage; 2012.","edition":"2"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02256-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02256-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02256-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T16:28:46Z","timestamp":1700411326000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02256-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,4]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2256"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02256-2","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,4]]},"assertion":[{"value":"12 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants were sent detailed information sheets informing them of the nature and purposes of the research. Written informed consent was obtained. All participants received a gift voucher as a \u2018thank you\u2019 for the time they gave attending interviews. Ethical approval for all elements of the study was granted by the UK Healthcare Research Authority and the South East Scotland Research Ethics Committee (20\/SS\/0061).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"S Fletcher. Unrestricted educational grant from Roche Products Limited and Chugai Pharma UK Ltd, speaker honoraria from Roche Products Limited, Bayer and Novo Nordisk, meeting support from Novo Nordisk and Bayer. K Jenner. Unrestricted educational grant from Roche Products Limited and Chugai Pharma UK Ltd. L. Pembroke. Unrestricted educational grant from Roche Products Limited and Chugai Pharma UK Ltd, Consultancy fees from Roche Products Limited, Bayer, Biomarin and Sobi, Speaker Honoraria from Biomarin, Sobi, Novo Nordisk and Chugai. M Holland. Unrestricted educational grant from Roche Products Limited and Chugai Pharma UK Ltd. K Khair. Unrestricted educational grant from Roche Products Limited and Chugai Pharma UK Ltd, Consultancy fees from Bayer, Novo Nordisk, Sobi and Takeda, Speaker honoraria from Bayer, Biomarin, Novo Nordisk, Sobi, Pfizer and Takeda.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"155"}}